Coronary Arterial 18F-Sodium Fluoride Uptake
A Novel Marker of Plaque Biology

Marc R. Dweck, MD,* † Marcus W. L. Chow,* † Nikhil V. Joshi, MD,* † Michelle C. Williams, MD,* † Charlotte Jones, BSc,* † Alison M. Fletcher, PhD,* † Hamish Richardson, BSc; † Audrey White,* Graham McKillop, MD,* † Edwin J. R. van Beek, PhD, † Nicholas A. Boon, MD,* James H. F. Rudd, PhD, † David E. Newby, DSc,* †

Edinburgh and Cambridge, United Kingdom

Objectives
With combined positron emission tomography and computed tomography (CT), we investigated coronary arterial uptake of 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) as markers of active plaque calcification and inflammation, respectively.

Background
The noninvasive assessment of coronary artery plaque biology would be a major advance particularly in the identification of vulnerable plaques, which are associated with specific pathological characteristics, including microcalcification and inflammation.

Methods
We prospectively recruited 119 volunteers (72 ± 8 years of age, 68% men) with and without aortic valve disease and measured their coronary calcium score and 18F-NaF and 18F-FDG uptake. Patients with a calcium score of 0 were used as control subjects and compared with those with calcific atherosclerosis (calcium score > 0).

Results
Inter-observer repeatability of coronary 18F-NaF uptake measurements (maximum tissue/background ratio) was excellent (intra-class coefficient 0.99). Activity was higher in patients with coronary atherosclerosis (n = 106) versus control subjects (1.64 ± 0.49 vs. 1.23 ± 0.24; p = 0.003) and correlated with the calcium score (r = 0.652, p < 0.001), although 40% of those with scores > 1,000 displayed normal uptake. Patients with increased coronary 18F-NaF activity (n = 40) had higher rates of prior cardiovascular events (p = 0.016) and angina (p = 0.023) and higher Framingham risk scores (p = 0.011). Quantification of coronary 18F-FDG uptake was hampered by myocardial activity and was not increased in patients with atherosclerosis versus control subjects (p = 0.498).

Conclusions
18F-NaF is a promising new approach for the assessment of coronary artery plaque biology. Prospective studies with clinical outcomes are now needed to assess whether coronary 18F-NaF uptake represents a novel marker of plaque vulnerability, recent plaque rupture, and future cardiovascular risk. (An Observational PET/CT Study Examining the Role of Active Valvular Calcification and Inflammation in Patients With Aortic Stenosis; NCT01358513) (J Am Coll Cardiol 2012:59:1539–48) © 2012 by the American College of Cardiology Foundation

Myocardial infarction (MI) is the foremost cause of death in developed countries (1) and confers a major economic, social, and healthcare burden worldwide (2). The majority of MIs result from rupture of atherosclerotic plaque, although identifying those at risk of rupture is problematic. The vast majority (86%) of culprit atherosclerotic lesions cause non-flow limiting luminal stenosis (3,4) that will not be detected by noninvasive stress testing. New methods focusing on plaque pathology are required to identify high-risk lesions so that risk of clinical events can be reduced by appropriate therapy.

Calcification is a key feature of human atherosclerosis, and its macroscopic presence in the coronary arteries can be detected by cardiac computed tomography (CT). Coronary...
artery calcium (CAC) scoring provides a surrogate measure of the atherosclerotic burden and a powerful predictor of cardiovascular risk (5). Risk prediction can be improved by examining the progression of coronary calcification (6,7) and by detecting spotty calcification (8). However, CT is unable to measure active calcification directly and cannot reliably detect micro-calculations that can lead to microfractures and acute thrombosis (9–11). 18F-sodium fluoride (18F-NaF) is an established positron emission tomography (PET) tracer that detects novel areas of bone formation and remodeling (12). Uptake has also been described in aortic and carotid atheroma where activity is believed to signal areas of active vascular calcification, although this is hypothetical (13–15). To date, 18F-NaF uptake has not been measured in the coronary vasculature.

Inflammation is thought to play a key role in plaque rupture. Histologically, the vulnerable plaque is characterized by a lipid-rich pool, infiltration of inflammatory cells, and a thin fibrous cap (4). Macrophages in particular are found in abundance within ruptured plaques and are thought to contribute to a pro-thrombotic state and degradation of the fibrous cap via the action of matrix metalloproteinases (16). Vascular inflammation can be assessed noninvasively in the carotid arteries, aorta, iliac, and femoral arteries with uptake of 18F-fluorodeoxyglucose (18F-FDG) as measured by combined PET and computed tomography (CT) (17). 18F-FDG uptake correlates with plaque macrophage burden (18), symptoms (19), and Framingham Risk Score (20) and can be lowered with statin and other therapies (21,22). Recent in vitro and ex vivo data have also suggested that 18F-FDG uptake might reflect plaque hypoxia (23). However, measurement of 18F-FDG uptake within coronary atheroma is challenging, because of cardiac and respiratory motion and the intense myocardial 18F-FDG uptake that can potentially swamp any plaque signal (24,25).

The aim of this study was to investigate coronary arterial uptake of 18F-NaF and 18F-FDG as markers of active calcification and inflammation, respectively. We hypothesized that the degree of uptake of both tracers would correlate with atherosclerotic disease severity, symptoms, prior cardiovascular events, and predictors of future clinical risk.

### Methods

#### Study population.

This was a substudy of a previously published prospective cohort of 121 apparently healthy volunteers and patients with aortic sclerosis and stenosis (26). All subjects were over 50 years of age and consecutively recruited from cardiology outpatient clinics (Royal Infirmary Edinburgh) to achieve groups of similar age and sex. Exclusion criteria included insulin-dependent diabetes mellitus, poorly controlled type 2 diabetes mellitus, women of childbearing potential not taking contraception, inability to undergo PET/CT scanning, and life expectancy <2 years. The study was approved by the local research ethics committee, and written informed consent was obtained from all subjects.

#### Baseline clinical assessment.

Baseline clinical assessment was performed on the day of the initial PET/CT scan and included current cardiac symptoms, prior coronary intervention (percutaneous coronary intervention and coronary artery bypass grafting), and past medical history of previous major adverse cardiovascular events (MACE) (MI, cerebrovascular accident, and coronary revascularization). Atherogenic risk factors such as age, sex, smoking habit, history of hypertension, diabetes mellitus, hypercholesterolemia, socioeconomic status, and family history of cardiovascular disease were identified. Full external examination was performed, and height and weight were measured to determine body mass index. A 12-lead electrocardiogram was performed, and venous blood was collected for measurement of serum creatinine, full lipid profile, and markers of calcium metabolism. On the basis of this information, Framingham risk scores for coronary heart disease (CHD), CHD death, cardiovascular disease (CVD), and CVD death were calculated.

#### Dietary restrictions.

Myocardial uptake of 18F-FDG can cause overspill of signal into the coronary arteries, leading to difficulties in discriminating coronary artery uptake from myocardium. All patients in our cohort were asked to observe a carbohydrate-free, high-fat diet for 24 h before their 18F-FDG scan. This suppresses myocardial uptake by switching the heart from glucose to free-fatty acid metabolism (27–29). Patients were provided with written instructions and contacted by phone the day before the scan in an attempt to ensure dietary compliance.

#### PET/CT image acquisition and reconstruction.

Subjects underwent combined PET/CT imaging of the aorta and coronary arteries with a hybrid scanner (Biograph mCT, Siemens Medical Systems, Erlangen, Germany). For the first scan, an electrocardiogram-gated breath-hold CT scan (non-contrast-enhanced, 40 mAs/rot [CareDose, Siemens Medical Systems], 100 kV) of the coronary arteries was performed for calculation of the CAC score. Study subjects were then administered a target dose of 125 MBq 18F-NaF intravenously and subsequently rested in a quiet environment for 60 min. An attenuation correction CT scan (non-enhanced 120 kV and 50 mA) was then performed, followed by PET imaging of the thorax in 3-dimensional mode for 10 min.
For the second scan, subjects were administered a target dose of 200 MBq 18F-FDG intravenously and subsequently rested in a quiet environment for 90 min. Combined PET/CT imaging was then performed as described for the 18F-NaF scan but with a 15-min bed time. Tracer circulation times were based on previous studies with 18F-FDG and 18F-NaF in atherosclerosis and aimed for optimal contrast between the aortic wall, coronary arteries, and the blood pool (14,15,19). The PET data were reconstructed with the Siemens Ultra-HD (time of flight +True X) reconstruction algorithm. Corrections were applied for attenuation, dead time, scatter, and random coincidences. All image analysis was performed on fused PET/CT datasets.

Image analysis: coronary arteries. Evaluation of the calcium score was performed with calcium score analysis software (VScore, Vital Images, Minnetonka, Minnesota). Vessel-specific and total Agatston calcium scores were calculated as described previously (30). The PET and CT images were fused and analyzed by an experienced reader with an Osirix workstation (OsirIX version 3.5.1 64-bit; OsirIX Imaging Software, Geneva, Switzerland). For 18F-NaF uptake, the coronary arteries were visually identified, and regions of interest were drawn around areas of maximal uptake in the left main stem, left anterior descending artery, circumflex artery, and the right coronary artery. The maximum standard uptake value (SUV) was recorded from these regions. It was not possible to determine the mean SUV values, given the difficulty in identifying the exact borders of the coronary arteries on the non-contrast-enhanced scans. The SUV is the decay-corrected tissue concentration of 18F-NaF divided by the injected dose/body weight. However, SUV measurements in vascular structures are influenced by variability in 18F-FDG and 18F-NaF activity in the blood. Therefore, SUV measurements were divided by an averaged mean SUV value in the blood pool, derived from 5 circular regions of interest drawn in the center of the superior vena cava. This provided maximum tissue/background ratios (TBRs) as a measure of arterial tracer uptake (18,31).

Quantification of 18F-FDG uptake was performed as for 18F-NaF but restricted to the proximal and mid-portions of the coronary vessels (24). Difficulties were still encountered as a result of the pervasive myocardial uptake observed with this tracer, and coronary activity was only quantified in areas where myocardial uptake could be confidently avoided.

INTER-OBSERVER REPEATABILITY OF IMAGE ANALYSIS. After the image analysis methodology was established, PET scans from 20 patients were selected at random from the cohort. All scans from these patients were analyzed independently by 2 trained observers (M.D., N.J.). This provided measures of inter-observer repeatability for maximum TBR values.

Image analysis: aorta. The uptake of 18F-FDG (32) and 18F-NaF (13) in the ascending and descending aorta was quantified as per published methods. Circular regions of interest were drawn around the aorta on adjacent 3-mm axial slices with care taken to avoid uptake from extravascular structures. Maximum SUV values were once more corrected for blood-pool activity to provide TBR values.

Statistical analysis. Comparisons of tracer uptake were initially made between those with and without calcific atherosclerosis. Patients with CAC scores >0 or a prior history of ischemic heart disease were considered to have underlying calcific coronary atherosclerosis. Patients with a CAC score of 0 and no past history of CHD were considered not to have calcific atherosclerosis and designated as control subjects. Patients with atherosclerosis were then divided according to well-established cutoffs in the coronary calcium score (0, 1 to 100, 101 to 400, 401 to 1,000, >1,000) (33) to assess the impact of disease severity on tracer activity. Finally, comparisons were made between subjects who had normal and increased 18F-NaF uptake. The highest maximum TBR value in the control group was used as the cutoff value above which 18F-NaF was deemed to be elevated. In patients with underlying calcific coronary atherosclerosis, those who had increased 18F-NaF uptake were defined as having active coronary calcification, whereas those with normal 18F-NaF uptake were defined as having inactive calcification.

Continuous variables were expressed as mean ± SD and compared with unpaired Student t test or 1-way analysis of variance where appropriate. Categorical variables were expressed as percentages and analyzed with the chi-square test. Correlations between normally distributed data were performed with Pearson’s correlation, whereas Spearman’s correlation was used for nonparametric data. The 95% normal range for differences between sets of SUV and TBR measurements (the limits of agreement) were estimated by multiplying the SD of the mean difference by 1.96 (34). Intra-class correlation coefficients with 95% confidence intervals (CIs) were calculated for intraobserver and interobserver variation. Statistical analysis was performed with SPSS software (version 18, SPSS, Inc., Chicago, Illinois). A 2-sided p value <0.05 was regarded as statistically significant.

Results

Baseline characteristics. A total of 119 patients were recruited (age 72 ± 8 years, 68% men, 66% with aortic stenosis) and had both 18F-NaF (66 ± 6 min after 124 ± 10 MBq) and 18F-FDG (94 ± 7 min after 198 ± 13 MBq) scans of their thorax <1 month apart (median 7 days, interquartile range 1 to 14 days). The effective radiation dose/patient, including all PET and CT scans, was 9.73 ± 1.19 mSv with a CT conversion factor of 0.014 mSv/mGy/cm.

Thirteen patients had no past history of coronary artery disease (CAD) or evidence of calcific coronary atherosclerosis and formed the control group (Table 1). A total of 106 patients had evidence of coronary atherosclerosis: 41 having a clinical diagnosis of prior CAD, and a further 65 having calcium scores above 0. One patient had experienced an
Table 1  Patient Demographic Data

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Control Ca Score 0</th>
<th>Ca Score 1–100</th>
<th>Ca Score 101–400</th>
<th>Ca Score 401–1,000</th>
<th>Ca Score &gt;1,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>119</td>
<td>13</td>
<td>19</td>
<td>23</td>
<td>27</td>
<td>37</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>72 ± 8</td>
<td>66 ± 7</td>
<td>69 ± 8</td>
<td>72 ± 8</td>
<td>70 ± 9</td>
<td>76 ± 7</td>
</tr>
<tr>
<td>Male, %</td>
<td>68</td>
<td>46</td>
<td>58</td>
<td>61</td>
<td>74</td>
<td>81</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>28 ± 4</td>
<td>28 ± 4</td>
<td>28 ± 3</td>
<td>28 ± 4</td>
<td>28 ± 4</td>
<td>27 ± 5</td>
</tr>
<tr>
<td>CHD, %</td>
<td>34</td>
<td>0</td>
<td>0</td>
<td>17</td>
<td>48</td>
<td>65</td>
</tr>
<tr>
<td>Angina, %</td>
<td>24</td>
<td>0</td>
<td>0</td>
<td>13</td>
<td>37</td>
<td>43</td>
</tr>
<tr>
<td>MACE, %</td>
<td>40</td>
<td>0</td>
<td>0</td>
<td>32</td>
<td>44</td>
<td>75</td>
</tr>
<tr>
<td>Previous MI</td>
<td>12</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>11</td>
<td>24</td>
</tr>
<tr>
<td>Previous CVA/TIA</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>14</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Previous PCI</td>
<td>15</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>22</td>
<td>27</td>
</tr>
<tr>
<td>Previous CABG</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>16</td>
</tr>
<tr>
<td>Smokers (ex or current), %</td>
<td>50</td>
<td>38</td>
<td>53</td>
<td>26</td>
<td>59</td>
<td>59</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>15</td>
<td>23</td>
<td>5</td>
<td>13</td>
<td>12</td>
<td>22</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>60</td>
<td>38</td>
<td>42</td>
<td>65</td>
<td>52</td>
<td>57</td>
</tr>
<tr>
<td>Hypercholesterolemia, %</td>
<td>49</td>
<td>38</td>
<td>39</td>
<td>39</td>
<td>59</td>
<td>57</td>
</tr>
<tr>
<td>Aortic stenosis, %</td>
<td>66</td>
<td>54</td>
<td>58</td>
<td>61</td>
<td>78</td>
<td>73</td>
</tr>
<tr>
<td>Aortic sclerosis, %</td>
<td>17</td>
<td>23</td>
<td>11</td>
<td>22</td>
<td>11</td>
<td>19</td>
</tr>
<tr>
<td>ACE/ARB, %</td>
<td>49</td>
<td>15</td>
<td>21</td>
<td>39</td>
<td>56</td>
<td>76</td>
</tr>
<tr>
<td>Beta-blockers, %</td>
<td>39</td>
<td>15</td>
<td>26</td>
<td>48</td>
<td>44</td>
<td>46</td>
</tr>
<tr>
<td>Statins, %</td>
<td>53</td>
<td>15</td>
<td>21</td>
<td>52</td>
<td>67</td>
<td>73</td>
</tr>
<tr>
<td>Total cholesterol, mg/dl</td>
<td>193 ± 50</td>
<td>227 ± 48</td>
<td>199 ± 41</td>
<td>204 ± 57</td>
<td>175 ± 44</td>
<td>181 ± 49</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dl</td>
<td>104 ± 44</td>
<td>123 ± 45</td>
<td>119 ± 37</td>
<td>112 ± 52</td>
<td>93 ± 36</td>
<td>94 ± 42</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dl</td>
<td>54 ± 20</td>
<td>69 ± 42</td>
<td>54 ± 12</td>
<td>52 ± 15</td>
<td>54 ± 18</td>
<td>51 ± 12</td>
</tr>
<tr>
<td>Creatinine, mg/dl</td>
<td>0.98 ± 0.33</td>
<td>0.97 ± 0.12</td>
<td>0.90 ± 0.13</td>
<td>0.93 ± 0.12</td>
<td>0.88 ± 0.14</td>
<td>0.86 ± 0.12</td>
</tr>
<tr>
<td>Calcium, mg/dl</td>
<td>9.30 ± 0.57</td>
<td>9.41 ± 0.23</td>
<td>9.41 ± 0.97</td>
<td>9.29 ± 0.61</td>
<td>9.24 ± 0.32</td>
<td>9.24 ± 0.49</td>
</tr>
<tr>
<td>Phosphate, mg/dl</td>
<td>3.55 ± 0.49</td>
<td>3.68 ± 0.55</td>
<td>3.57 ± 0.55</td>
<td>3.51 ± 0.40</td>
<td>3.53 ± 0.40</td>
<td>3.54 ± 0.48</td>
</tr>
<tr>
<td>Alk Phosphatase, U/l</td>
<td>84 ± 44</td>
<td>93 ± 23</td>
<td>83 ± 25</td>
<td>79 ± 20</td>
<td>80 ± 23</td>
<td>77 ± 27</td>
</tr>
<tr>
<td>Ca score</td>
<td>414 (79–1,251)</td>
<td>0 (0–0)</td>
<td>19 (2–46)</td>
<td>277 (125–351)</td>
<td>734 (448–888)</td>
<td>1783 (1,357–3,410)</td>
</tr>
<tr>
<td>18F-NaF Max SUV</td>
<td>1.56 ± 0.50</td>
<td>1.21 ± 0.26</td>
<td>1.28 ± 0.27</td>
<td>1.40 ± 0.27</td>
<td>1.49 ± 0.31</td>
<td>1.97 ± 0.60</td>
</tr>
<tr>
<td>18F-NaF Max TBR</td>
<td>1.59 ± 0.48</td>
<td>1.23 ± 0.22</td>
<td>1.33 ± 0.32</td>
<td>1.42 ± 0.27</td>
<td>1.59 ± 0.29</td>
<td>1.97 ± 0.58</td>
</tr>
<tr>
<td>Patients with increased coronary 18F-NaF, %</td>
<td>34%</td>
<td>0%</td>
<td>5%</td>
<td>26%</td>
<td>41%</td>
<td>59%</td>
</tr>
<tr>
<td>18F-FDG Max SUV</td>
<td>1.54 ± 0.24</td>
<td>1.43 ± 0.30</td>
<td>1.56 ± 0.19</td>
<td>1.55 ± 0.27</td>
<td>1.46 ± 0.24</td>
<td>1.60 ± 0.22</td>
</tr>
<tr>
<td>18F-FDG Max TBR</td>
<td>1.22 ± 0.21</td>
<td>1.18 ± 0.31</td>
<td>1.25 ± 0.18</td>
<td>1.19 ± 0.16</td>
<td>1.22 ± 0.29</td>
<td>1.24 ± 0.15</td>
</tr>
</tbody>
</table>

10-yr Framingham risk scores

- **CVD**: 30 ± 13, 25 ± 17, 27 ± 13, 31 ± 10, 27 ± 12, 35 ± 13
- **CVD death**: 14 ± 10, 8 ± 9, 11 ± 8, 14 ± 8, 12 ± 10, 18 ± 11
- **CHD**: 19 ± 12, 16 ± 15, 18 ± 11, 20 ± 10, 18 ± 12, 22 ± 12
- **CHD death**: 6.3 ± 4.7, 4.5 ± 5.4, 5.2 ± 3.9, 6.3 ± 3.6, 5.3 ± 4.4, 8.3 ± 5.1

Acute coronary syndrome in the week before his 18F-NaF scan; otherwise, patients had stable CHD.

**Dietary restrictions.** Average myocardial SUV across the entire cohort was 4.6 ± 3.6, and dietary restrictions effectively suppressed 18F-FDG myocardial uptake (prespecified as a maximum SUV <5 measured in the maximal area of uptake in the left ventricular septum) in 67% of patients, similar to that seen in previous studies (24). Sixty-one percent of patients complied with the dietary restrictions, on the basis of dietary diaries, and had lower myocardial 18F-FDG uptake than non-compliers (SUV $3.2 \pm 2.3$ vs. $6.7 \pm 4.2; p < 0.001$).

**18F-NaF coronary uptake.** Coronary 18F-NaF uptake was quantifiable in 96% of the coronary territories examined. It was not possible to assess the left main stem in 20 patients, due to overspill of activity from the aortic valve secondary to calcific aortic stenosis (Table 2). Repeatability studies were excellent for coronary 18F-NaF quantification with no fixed or proportional biases, limits of agreement of $\pm 0.14$ for maximum TBR values (Fig. 1), and an intra-class
correlation coefficient value of 0.99 (95% CI: 0.98 to 1.00). Limits of agreement for 18F-NaF were in the order ±0.20 when examined in each of the coronary territories (Table 2).

18F-NaF activity was observed in areas overlying, adjacent to, and remote from existing coronary calcification. Uptake was focal in nature and could be localized to individual coronary plaques. Areas of coronary calcification with no 18F-NaF uptake were also commonly observed (Fig. 2).

Coronary 18F-NaF uptake was higher in those with coronary atherosclerosis, compared with the control group (1.64 ± 0.49 vs. 1.23 ± 0.24; p = 0.003) (Table 1). The highest maximum TBR value in the control group was 1.61, which was used to divide patients with coronary atherosclerosis into those with increased 18F-NaF uptake (active calcification; TBR maximum >1.61; n = 40) and those without (inactive calcification; TBR maximum ≤1.61; n = 66) (Fig. 2, Table 3).

Patients with increased 18F-NaF uptake were older, more likely to be male, and had lower serum high-density lipoprotein cholesterol concentrations than those without increased uptake (Table 3). Overall statin use was similar between the groups, although atorvastatin use seemed to be double in those with active calcification (28% vs. 14%; p = 0.077). They also had higher calcium scores, and there was a strong correlation between the CAC score and 18F-NaF uptake (r = 0.652, p < 0.001). However extensive overlap was observed, with some patients with increased 18F-NaF uptake having relatively little coronary calcification (minimum Agatston score 98) and patients without 18F-NaF uptake having extensive calcium (maximum Agatston score 4,636). Indeed 41% of patients with CAC scores >1,000 had no significant 18F-NaF uptake (Table 1).

Sites of increased 18F-NaF uptake were evenly distributed across the coronary vasculature (Table 2), and activity was 50% higher on average in these plaques compared with inactive plaques in the same patient (2.14 ± 0.42 vs. 1.43 ± 0.32; p < 0.001). In 25 patients, significant uptake was observed in 2 or more coronary territories.

Patients with high 18F-NaF uptake were more likely to have a clinical diagnosis of CAD (60% vs. 26%; p < 0.001), anginal symptoms (40% vs. 20%; p = 0.023), prior revascularization (38% vs. 11%; p = 0.001), and previous MACE (45% vs. 23%; p < 0.016) (Table 3). Furthermore, cardiovascular risk factor burden was increased. Framingham risk prediction scores were higher in those with increased 18F-NaF uptake in terms of Framingham CVD (p = 0.033), CHD (p = 0.049), CVD death (p = 0.011), and CHD death (p = 0.024) (Fig. 3, Table 3). Interestingly 10-year Framingham risk scores for CVD, CVD death, and CHD death all displayed a correlation with 18F-NaF coronary uptake but not with the CAC score (Table 4). Framingham risk scores are not designed for patients with prior cardiovascular events. If these patients were excluded from the analysis, risk scores remained higher in those with active calcification for both CHD (18 ± 12 vs. 26 ± 12; p = 0.020) and CVD (29 ± 13 vs. 37 ± 12; p = 0.017).

One patient was assessed 1 week after sustaining an inferior non–ST-segment elevation MI. Intense uptake was observed in the proximal right coronary artery, which had been felt clinically to be the culprit coronary artery (on the basis of dynamic changes on the electrocardiogram and appearances at invasive coronary angiography). Relatively little uptake was observed in his other coronary territories, despite having 3-vessel CAD and extensive coronary calcification (Fig. 2, Online Video).

18F-FDG coronary uptake. The 18F-FDG uptake was difficult to quantify, particularly in the left main stem and circumflex artery. It was not possible to quantify accurately in 49% of the vessel territories examined (Table 2). This was largely the result of myocardial spill over into the coronary arteries, which was observed despite the dietary restrictions imposed in the study. Even when possible, coronary 18F-FDG repeatability was inferior to that for 18F-NaF, with a
fixed bias of 0.22, limits of agreement of 0.32 and an intra-class correlation coefficient value of 0.67 (95% CI: 0.31 to 0.86) (Fig. 1).

There were no differences in 18F-FDG uptake between the control group and those with atherosclerosis (1.18 ± 0.31 vs. 1.23 ± 0.20; p = 0.498) (Table 1). There also was no correlation between 18F-FDG activity and the CAC score, whether in the coronary vasculature as a whole (r = 0.063, p = 0.538) or on a vessel-by-vessel basis (LAD: r = −0.041, p = 0.705; RCA: r = 0.039, p = 0.726). The 18F-FDG coronary uptake was not associated with increased rates of CAD, anginal symptoms, prior coronary revascularization, or previous MACE. Neither was there a significant correlation with any of the risk prediction scores (Table 4).

Aortic uptake. 18F-NaF uptake in the aorta was observed in a focal distribution most commonly in areas overlying or adjacent to existing aortic calcification (Fig. 4). Less frequently 18F-NaF uptake occurred in the absence of local calcium (Fig. 4, Table 2). Across the cohort as a whole, 18F-NaF uptake in the aorta was higher than in the coronary arteries (2.01 ± 0.31 vs. 1.59 ± 0.48; p < 0.001) (Table 2). Uptake in the ascending aorta correlated with activity in the descending aorta (r = 0.815, p < 0.001) and the coronary arteries (r = 0.525, p < 0.001) and with Framingham risk scores (e.g., ascending aorta vs. CVD: r = 0.208, p = 0.024). However, among those with increased coronary 18F-NaF activity, a correlation was no longer observed between activity in the coronary vasculature and the aorta (r = 0.157, p = 0.333).
18F-FDG uptake was observed in a circumferential pattern around the aortic wall as previously described (Fig. 4) (17). Maximum 18F-FDG TBR in the ascending aorta correlated strongly with that in the descending aorta (r = 0.824, p < 0.001) and the coronary arteries (r = 0.543, p < 0.001). 18F-FDG activity was higher in the aorta than the coronary arteries (1.78 ± 0.25 vs. 1.22 ± 0.21; p < 0.001) (Table 2). There was no correlation between 18F-NaF and 18F-FDG uptake in the ascending aorta (r = 0.043, p = 0.647), descending aorta (r = 0.124, p = 0.183), or the coronary arteries (r = 0.127, p = 0.21).

**Discussion**

This is the first study to describe 18F-NaF uptake in the coronary arteries with PET/CT. We have demonstrated that this technique is both feasible and repeatable and that it can provide key insights into coronary artery plaque biology. Activity was higher in patients with atherosclerosis compared with control subjects, displaying a progressive rise with increasing atherosclerotic burden. Furthermore, 18F-NaF uptake can be used to discriminate between those patients with active and inactive coronary calcification. Those with active calcification (38%) were more likely to have clinically significant CAD, a higher incidence of previous MACE, lower serum high-density lipoprotein cholesterol concentrations, and higher Framingham risk prediction scores. Therefore, 18F-NaF holds promise as a means of identifying high-risk populations and refining the predictive power of CAC scoring. Finally, the spatial resolution of PET/CT allows localization of the 18-NaF signal to specific coronary territories and plaques offering the possibility of identifying vulnerable or culprit plaque on an individual basis.

18F-NaF uptake has been described recently in the aorta (14) and carotid arteries (15) and is believed to reflect active vascular calcification. Although histological validation of this hypothesis is lacking, mechanistic information can be extrapolated from 18F-NaF uptake in bone that has been studied for over 30 years. In that tissue, 18F-NaF is incorporated directly into exposed hydroxyapatite crystal via an exchange mechanism with hydroxyl groups (35). Therefore it detects novel areas of calcification as well as regions of remodeling and is used clinically in Paget’s disease (36), primary osteoblastic tumors, and metastatic bone disease (37). Similarly, we believe that coronary uptake reflects active calcification in atherosclerotic plaque. Certainly coronary 18F-NaF uptake seems to offer information that is additional and complementary to CAC scoring. Although 18F-NaF activity was most commonly observed overlying
existing calcium and a strong correlation was observed with the CAC score, 41% of patients with scores >1,000 had no significant 18F-NaF uptake and, areas of increased tracer uptake were also found in regions remote from established calcium. This activity potentially relates to developing microcalcification that is frequently beyond the resolution of CT and believed to be associated with increased mechanical stress and risk of future cardiovascular events (9–11). Therefore, 18F-NaF seems to distinguish between patients with dormant calcific disease, established many months or years previously, and subjects with metabolically active disease where the calcification process is ongoing. Importantly this distinction seems to be of clinical relevance, with higher rates of anginal symptoms, prior MACE events, and cardiovascular risk factor scores observed in those with active disease.

Calcification plays a key role in the pathophysiology of atherosclerosis, although its triggers remain debated. Atherosclerotic plaques with healed rupture almost invariably contain calcium (38,39), leading to the hypothesis that calcification forms part of a healing response to such events (7,40,41). The spatial resolution of PET/CT is sufficient to localize 18F-NaF activity to specific coronary territories, indicating that inflammation and calcification occur independently in these regions.

By contrast to 18F-NaF, 18F-FDG activity was not increased in patients with coronary atherosclerosis, compared with control subjects. However, our data were hampered by myocardial uptake that rendered one-half of the coronary territories un-interpretable. This largely reflected the imperfect dietary compliance that occurred in one-third of patients, despite the detailed written instructions and verbal reminders provided. Further studies are required in younger cohorts in whom compliance might be improved, although our data do suggest that 18F-FDG might be of limited use in the assessment of stable coronary disease. Inflammation has a more prominent role in acute coronary syndromes, and therefore 18-FDG might provide more information in these patients. Indeed a recent study demonstrated increased 18F-FDG uptake in unstable versus stable plaque in the proximal coronary vasculature (24).

**Study limitations.** Positron emission tomography/CT is expensive, especially when compared with circulating biomarkers of calcification activity, and this might limit its clinical use.

---

**Table 4**

**Correlation of 10-Year Framingham Risk Scores With the Coronary Calcium Score and PET Uptake**

<table>
<thead>
<tr>
<th>10-Yr Framingham Risk Scores</th>
<th>CVD Events</th>
<th>CVD Death</th>
<th>CHD Events</th>
<th>CHD Death</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Coronary calcium score</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>r = 0.112</td>
<td>r = 0.152</td>
<td>r = 0.047</td>
<td>r = 0.110</td>
<td></td>
</tr>
<tr>
<td>p = 0.230</td>
<td>p = 0.101</td>
<td>p = 0.617</td>
<td>p = 0.237</td>
<td></td>
</tr>
<tr>
<td><strong>18F-NaF max TBR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary arteries</td>
<td>r = 0.196</td>
<td>r = 0.282</td>
<td>r = 0.138</td>
<td>r = 0.220</td>
</tr>
<tr>
<td>p = 0.035*</td>
<td>p = 0.002†</td>
<td>p = 0.137</td>
<td>p = 0.017*</td>
<td></td>
</tr>
<tr>
<td>Ascending aorta</td>
<td>r = 0.208</td>
<td>r = 0.239</td>
<td>r = 0.141</td>
<td>r = 0.195</td>
</tr>
<tr>
<td>p = 0.024*</td>
<td>p = 0.009†</td>
<td>p = 0.129</td>
<td>p = 0.035*</td>
<td></td>
</tr>
<tr>
<td>Descending aorta</td>
<td>r = 0.199</td>
<td>r = 0.231</td>
<td>r = 0.144</td>
<td>r = 0.191</td>
</tr>
<tr>
<td>p = 0.032*</td>
<td>p = 0.012*</td>
<td>p = 0.122</td>
<td>p = 0.039*</td>
<td></td>
</tr>
<tr>
<td><strong>18F-FDG max TBR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary arteries</td>
<td>r = −0.024</td>
<td>r = 0.118</td>
<td>r = 0.059</td>
<td>r = 0.060</td>
</tr>
<tr>
<td>p = 0.815</td>
<td>p = 0.245</td>
<td>p = 0.565</td>
<td>p = 0.560</td>
<td></td>
</tr>
<tr>
<td>Ascending aorta</td>
<td>r = −0.018</td>
<td>r = −0.047</td>
<td>r = 0.031</td>
<td>r = 0.012</td>
</tr>
<tr>
<td>p = 0.845</td>
<td>p = 0.618</td>
<td>p = 0.741</td>
<td>p = 0.899</td>
<td></td>
</tr>
<tr>
<td>Descending aorta</td>
<td>r = −0.043</td>
<td>r = −0.052</td>
<td>r = 0.030</td>
<td>r = −0.019</td>
</tr>
<tr>
<td>p = 0.645</td>
<td>p = 0.584</td>
<td>p = 0.752</td>
<td>p = 0.842</td>
<td></td>
</tr>
</tbody>
</table>

Correlation of 10-year Framingham risk scores with the coronary calcium score and 18F-NaF or 18F-FDG uptake in the coronary arteries and aorta.

* p < 0.05; †p < 0.01

Abbreviations as in Table 1.
However, we have demonstrated that—among those with increased 18F-NaF uptake—activity in the coronaries did not correlate with that in the aorta, suggesting that it is driven by local rather than systemic factors. Therefore blood-based biomarkers are unlikely to provide an accurate indication of coronary calcification activity and instead will tend to reflect that within larger vessels or skeletal bone. Therefore, in our opinion the added costs of PET/CT are justified by its unique ability to measure calcification activity specific to the coronary vasculature. Moreover, 18F-NaF is a very simple and relatively cheap ligand to produce.

The majority of our patients had either concomitant aortic stenosis or aortic sclerosis. Although atherosclerosis and aortic stenosis often co-exist and share many common etiological factors and histopathological similarities, it is nevertheless important to confirm these findings in a cohort of patients more representative of the clinical population with atherosclerosis in the absence of aortic stenosis.

Finally, risk prediction scores are intended to predict events in asymptomatic patients and therefore are not strictly applicable to subjects with an established clinical diagnosis of ischemic heart disease or aortic valve disease. Given these issues, we acknowledge that our data with respect to risk prediction are preliminary and need validation in further prospective clinical trials. However, these scores remained higher in patients with increased coronary NaF uptake even after patients with prior MACE were excluded from the analysis. Therefore we believe that this approach has helped to establish an association between 18F-NaF activity and the presence of traditional cardiovascular risk factors and provides a potential assessment of the risk of future cardiovascular events.

Conclusions

18F-NaF holds promise as a noninvasive method for investigating the role of active calcification in coronary atherosclerosis. There was a strong correlation with established coronary calcium, but 41% of patients with calcium scores >1,000 had no significant 18F-NaF uptake. This suggests that 18F-NaF uptake provides different information, relating to metabolically active calcific plaque and developing micro-calcification. Moreover, this information seems to be of clinical significance in relation to symptomatic status, prior MACE events, and cardiovascular risk scores. Prospective studies to determine the relationship between 18F-NaF uptake, morphological plaque characteristics, and future cardiovascular events are now needed in subjects with stable and unstable CAD.

Acknowledgments

The authors are grateful to the Wellcome Trust Clinical Research Facility and the Clinical Research Imaging Centre for their help with this study.

Reprint requests and correspondence: Dr. Marc Dweck, Centre for Cardiovascular Science, University of Edinburgh, Little France Crescent, Edinburgh EH16 4TJ, United Kingdom. E-mail: MDweck@staffmail.ed.ac.uk.

REFERENCES

Dweck et al.
Coronary Arterial 18F-NaF Uptake


Key Words: acute coronary syndrome • inflammation • positron emission tomography • risk prediction.

APPENDIX

For a supplemental video, please see the online version of this article.